TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02715609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Gluconate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Gluconate
Study: NCT03534401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ARCHES Kenya
Description: ARCHES: Contraceptive counselors in intervention clinics will receiving training to ) provide counseling and education regarding risk of partner detection of contraceptive methods, and women's and girls' strategies to use contraceptive methods to minimize partner detection risk integrated into standard contraceptive counseling, b) make brief inquiries to allow clients the opportunity to disclose experiences of RC and IPV (i.e., screening), c) provide method-specific counseling based on this information and the method chosen by the client, d) provide supported linkage of IPV survivors to local IPV support services (i.e. warm referral), and e) offer palm-sized educational materials on RC and IPV, as well as IPV services to all clients.
Study: NCT03768804

Intervention type: OTHER
Group type: OTHER
Intervention: SyncAV algorithm on
Description: Cardiac Resynchronisation Device will be set to have the SyncAV algorithm on for the duration of the cardiopulmonary exercise test (CPET), before being reset to pre-existing settings

Intervention type: OTHER
Group type: OTHER
Intervention: SyncAV algorithm off
Description: ardiac Resynchronisation Device will be set to have the SyncAV algorithm off and a fixed AV delay, for the duration of the CPET, before being reset to pre-existing settings
Study: NCT01939665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife Irreversible electroporation (IRE)
Description: Tumor ablation with irreversible electroporation with the NanoKnife
Study: NCT03404687

Intervention type: RADIATION
Intervention: ultrasound
Description: for assessment of adnexal masses size and pattern
Study: NCT02715609

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study: NCT02818907

Intervention type: OTHER
Group type: OTHER
Intervention: Additional biological samples
Description: blood and tumor tissue samples
Study: NCT04230304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study: NCT01607957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
Study: NCT03582475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01899521

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy
Description: Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy
Description: Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy
Description: Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bronchoscopy
Description: Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc sulfate 220 mg once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc sulfate 220 mg once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: S-adenosylmethionine 400 mg twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: S-adenosylmethionine 400 mg twice daily
Study: NCT04042441

Intervention type: DRUG
Intervention: Insulin Degludec/Insulin Aspart
Description: Insulin Degludec/Insulin Aspart (Ryzodeg®) as prescribed by the patient's treating physician. The decision to initiate or switch into treatment with commercially available Ryzodeg® has been made before, and independently from, the decision to include the patient in this study.
Study: NCT04267120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be provided by Merck.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Merck will provide pembrolizumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood collection
Description: -Within 2 weeks prior to first dose of study drug, cycle 4 day 1, and at the off-treatment assessment
Study: NCT02753270

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short catheter
Description: Ultrasound Guided Foam Sclerotherapy in Great Saphenous Vein, measuring from 6 to 10 mm, with Short Catheter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long catheter preceded by tumescence
Description: Ultrasound Guided Foam Sclerotherapy Transcatheter in Great Saphenous Vein, measuring from 6 to 10 mm, Preceded by Tumescence.
Study: NCT00734149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study: NCT02422745

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa extract
Description: 2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa extract
Description: 2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Multivitamin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Multivitamin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa extract placebo
Description: Cocoa extract placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa extract placebo
Description: Cocoa extract placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin placebo
Description: Multivitamin placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamin placebo
Description: Multivitamin placebo
Study: NCT04747964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0601 for Injection
Description: Subjects will receive one single lowest dose of STSP-0601 for Injection following protocol requirements

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0601 for Injection
Description: Subjects will receive one single low dose of STSP-0601 for Injection following protocol requirements

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0601 for Injection
Description: Subjects will receive one single low-intermediate dose of STSP-0601 for Injection following protocol requirements

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0601 for Injection
Description: Subjects will receive one single intermediate dose of STSP-0601 for Injection following protocol requirements

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0601 for Injection
Description: Subjects will receive one single high dose of STSP-0601 for Injection following protocol requirements

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0601 for Injection
Description: Subjects will receive one single highest dose of STSP-0601 for Injection following protocol requirements
Study: NCT04179175

Intervention type: DRUG
Group type: OTHER
Intervention: secukinumab
Description: secukinumab 300mg every 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: secukinumab
Description: secukinumab 300mg every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: secukinumab
Description: secukinumab 300mg every 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: secukinumab
Description: secukinumab 300mg every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: secukinumab
Description: secukinumab 300mg every 4 weeks
Study: NCT01652235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith® p-Branch® or Zenith® Fenestrated AAA Endovascular Graft
Description: Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
Study: NCT04559815

Intervention type: DRUG
Intervention: Oral Semaglutide
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study: NCT06547684

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fESWT
Description: Shock wave therapy will be applied with Duolith SD1 device (Storz Medical, Tagerwilen, Switzerland). Therapy will be administered in the gastrocnemius medial and lateral and in the soleus muscles.~Parameters: 0.15mJ/mm2, 4-5 Hz, 1500 shoots/muscle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fESWT
Description: Shock wave therapy will be applied with Duolith SD1 device (Storz Medical, Tagerwilen, Switzerland). Therapy will be administered in the gastrocnemius medial and lateral and in the soleus muscles.~Parameters: 0.15mJ/mm2, 4-5 Hz, 1500 shoots/muscle.
Study: NCT04282187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Given PO
Study: NCT04200534

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care counseling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Given nicotine patches

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Receive counseling over the phone
Study: NCT03043794

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy SBRT
Description: Stereotactic Body Radiation Therapy to the breast to 21 Gy
Study: NCT04410978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Pharmaceutical form: Tablet~Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide HMR1726
Description: Pharmaceutical form: Tablet~Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match Tolebrutinib
Description: Pharmaceutical form: Tablet~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match Teriflunomide
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Study: NCT03404687

Intervention type: DIAGNOSTIC_TEST
Intervention: cancer antigen 125 level
Description: for prediction of malignancy

Intervention type: RADIATION
Intervention: Doppler
Description: for detection of blood flow
Study: NCT05936294

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Optimization of CRT Device
Description: Each patient will have atrial pacing 10% higher than the sinus rate or atrial pacing at a rate of 60 bpm if significant sinus bradycardia is present. Each patient will have six ECGs and echocardiographic sequences performed in the same session. In addition six electrical activation evaluations by the Medtronic ECG belt will be done as well. The first study will always be with no ventricular pacing. One study will be echocardiography-optimized BIV pacing and four studies for echocardiography-optimized (?) adaptive RV-only pacing with different AV intervals. A random-sequence will be performed to determine the order for the rest of the studies.
Study: NCT01231906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01529203

Intervention type: DRUG
Group type: OTHER
Intervention: Botulinum Toxin Type A (Azzalure)
Description: Powder for solution for injection

Intervention type: DEVICE
Group type: OTHER
Intervention: Restylane ranges
Description: Hyaluronic acid (HA) 20 mg/mL + Lidocaine 0.3% (Restylane® Lidocaine, Restylane® Perlane™ Lidocaine, Restylane® SubQ Lidocaine, Restylane® Lip Volume, Restylane® Lip Refresh)
Study: NCT01778257

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mate extract
Description: Mate is a South American herb that is traditionally prepared as a tea and used, among others, for weight reduction.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Amount and calorie of placebo are same with Mate extracts.
Study: NCT00691327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natrelle(TM) Silicone-Filled Breast Implants
Description: Breast implant surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natrelle(TM) Silicone-Filled Breast Implants
Description: Breast implant surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natrelle(TM) Silicone-Filled Breast Implants
Description: Breast implant surgery
Study: NCT01471496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prophylactic injection therapy
Description: Standard application of endoscopic injection therapy as it is used for actively bleeding ulcers, 10 ml of serum saline with 1/10000 epinephrine is submucosally injected to the four quadrants of the ulcer margins.
Study: NCT01231906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT03996824

Intervention type: OTHER
Intervention: Peroperative collect of inner ear cells
Description: After obtaining an informed consent during the preoperative medical visit, and if a non-conservative approach (translabyrinthine or transotic) is decided, the collect of inner ear cells will be performed during surgical approach.~The sample will be collect in a sterile tube, and carried to the laboratory were it will be placed bon cell culture.
Study: NCT00498875

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire regarding mood, coping with cancer, how closely you follow your treatment schedule, your thoughts, your demographic information (such as age and race), and your medical history. If the answers to your questionnaire indicate that you may be depressed, you will be offered the intervention portion of the study.

Intervention type: BEHAVIORAL
Intervention: Depression Intervention
Description: Sessions given over 7 weeks and each lasting 30-45 minutes, that use cognitive-behavioral techniques.
Study: NCT05203302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-Electrode Pulse Train
Description: AIM 2 - Stimuli will be presented on one of three electrodes (apical, middle, and basal) at an amplitude between 10 and 100% dynamic range in µAs in 10% dynamic range steps. Stimulation will be delivered at a rate of 1000 pps. The process will be repeated in random order until 20 loudness estimates are obtained for each stimulus (3 electrodes x 2 rates x 10 amplitudes) for each subject. The dynamic range will be determined by measuring the maximum acceptable loudness (MAL) and threshold for each of the stimuli. MAL will be measured by slowly raising the current level for each stimulus until the subject reports that it is as loud as they are willing to accept without becoming uncomfortably loud.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-Electrode Pulse Train
Description: AIM 2 - Stimuli will be presented on one of three electrodes (apical, middle, and basal) at an amplitude between 10 and 100% dynamic range in µAs in 10% dynamic range steps. Stimulation will be delivered at a rate of 1000 pps. The process will be repeated in random order until 20 loudness estimates are obtained for each stimulus (3 electrodes x 2 rates x 10 amplitudes) for each subject. The dynamic range will be determined by measuring the maximum acceptable loudness (MAL) and threshold for each of the stimuli. MAL will be measured by slowly raising the current level for each stimulus until the subject reports that it is as loud as they are willing to accept without becoming uncomfortably loud.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modulation Detection Threshold (MDT) and Gap Detection Tasks
Description: AIM 1 - MDT will be set at 150 Hz. Testing will be conducted in soundfield in a sound booth at 60 dB Sound Pressure Level (SPL) while the participant listens with both implants adjusted to user setting.
Study: NCT00140751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (drug)
Study: NCT02114710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
Study: NCT01524601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20 mg rosuvastatin for 4 weeks
Study: NCT03482401

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol
Description: Patients consume 3 capsules/day (474 mg phenolics/day) from the biopsy-confirmed breast cancer diagnosis to the surgery
Study: NCT02988518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COGMED program
Description: Patient should connect on his computer at home, 5 times a week, for 5 weeks. Every day, the patient has to do 8 exercises for a total duration of 30 to 45 minutes.~In total, the patient will have to complete 25 sessions. The difficulty level of the proposed items adjust automatically to the patient's maximum capacity to compel him to provide a cognitive effort. A progression index assesses the progress made by the patient.~Every week, the investigator will call the patient for 10 minutes in order to gather the patient's feelings, his difficulties, provide some advice and encourage him.~The investigator will have to analyze the results of curves available for each event, as well as the patient's progress index.
Study: NCT01530451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: 120mg OD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: 120mg OD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: one tab OD